ECS on MSP
Expert Insight into the Latest News & Updates for Medicare Secondary Payer Compliance
A widely used opioid-acetaminophen combination product, oxycodone/APAP 7.5-325mg and 10-325mg, has seen a significant drop in price! This will dramatically mitigate the Part D allocation
Medicare Advantage organizations (MAOs) earned another small victory with a favorable ruling on a motion to dismiss out of Federal Court in Boston. The case, MSP
Lyrica® (pregabalin) is at last available generically through manufacturer/distributor, Rising Pharmaceuticals! The exclusive patent was extended for six months when Lyrica® was approved for pediatric
Ready to talk?
Schedule a conversation with an ECS expert